Leaflet PULMOZYME 1mg / ml inhalation solution

Product code:
W51323001
Quantity:
6
Indicated for:
cystic fibrosis
Route of administration:
inhalation
Substance:
dornase alfa (enzyme)
ATC
R05CB13 — Respiratory system | Expectorants, excl. combinations with cough suppressants | Mucolytics
Dornaza alfa is a medication used for the treatment of cystic fibrosis. It is a recombinant enzyme that breaks down DNA in the thick mucus accumulated in the lungs, facilitating its clearance and improving respiratory function.

The medication is administered via inhalation, usually once daily, using a nebulizer. It is effective in reducing the frequency of respiratory infections and alleviating respiratory symptoms.

Side effects may include sore throat, hoarseness, skin rash, and, in rare cases, severe allergic reactions. Regular monitoring is essential to assess treatment effectiveness.

Consult your doctor to discuss the benefits and risks of treatment with Dornaza alfa. Follow the usage instructions to ensure therapy effectiveness.

General data about PULMOZYME 1mg / ml

Substance:
dornase alfa
Date of latest medicines list:
01-07-2016
Product code:
W51323001
Concentration:
1mg / ml
Pharmaceutical form:
inhalation solution
Quantity:
6
Product type:
Original
Prescription status:
P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Pharmaceutical forms available for dornase alfa

Concentrations available for dornase alfa

  • 1mg/ml
  • 2500U/2.5ml